| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Trevi Therapeutics, Inc.$17.84
-0.56 (-3.04%)
C 42Pipeline Score Overvalued Biotech · Commercial
Market Cap
2.01 B
EPS
-0.32
P/E Ratio
-
Value Trade
9.68 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
9.94 M
Operating CF
-16.69 M
Total Assets
179.61 M
Total Liabilities
7.48 M
Equity
172.13 M
D/E Ratio
12,345
-4.66 %
Week
-4.01 %
1 Month
34.96 %
3 Month
33.43 %
6 Month
566.54 %
5 Year
48.74 %
All Time
Cash Data
Cash Position
171.78 M
Monthly Burn
5.56 M
Runway
28.9 mo
Burn Trend
SEC Filing
May 5, 2026
Overview
Volume
1.03 M
52 Week Range
5.38 - 16.12
% held by Insiders
34.77 %
% held by Institutions
71.8 %
Enterprise Value
1.84 B
Total Shares
141.98 M
Short %
11.73 %
Float Shares
118.27 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Trevi Therapeutics, Inc.
344Total events
3Upcoming
55Tier-1 (high impact)
2019 – 2030Coverage
Upcoming catalysts 3
Event history 341
May 19, 2026
◆Poster PresentationPresentation
Poster on effect of nalbuphine ER on breathlessness in IPF patients from CORAL trial at ATS 2026
IPF-related chronic coughsource ↗
May 18, 2026
◆Oral PresentationHaduvioPresentation
Data Highlights from Trevi's ATS 2026 Presentations
chronic cough in IPF, non-IPF ILD, and RCCsource ↗
May 18, 2026
◆Oral PresentationPresentation
Oral presentation of primary and subgroup analyses from Phase 2b CORAL trial of nalbuphine ER for IPF-related chronic cough at ATS 2026
IPF-related chronic coughsource ↗
May 18, 2026
◆Poster PresentationPresentation
Poster on nalbuphine ER reducing cough bouts in RCC patients from RIVER trial at ATS 2026
refractory chronic coughsource ↗
May 18, 2026
◆Poster PresentationPresentation
Poster on burden of chronic cough in ILD patients from US survey at ATS 2026
interstitial lung diseasesource ↗
May 17, 2026
◆Poster PresentationPresentation
Poster on pharmacokinetics and safety of nalbuphine ER co-administered with pirfenidone or nintedanib at ATS 2026
IPF-related chronic coughsource ↗
May 12, 2026
◆Oral PresentationHaduvioPresentation
Corporate Presentation at Bank of America Global Healthcare Conference 2026
chronic cough in IPF, non-IPF ILD, and RCCsource ↗
May 7, 2026
◆R&D DayHaduvioPresentation
Trevi Therapeutics Investor and Analyst Day
chronic cough in IPF, non-IPF ILD, and RCCsource ↗
May 5, 2026
May 5, 2026
Drug Pipeline Intelligence
C42
Pipeline Score $504M
Pipeline ValueOvervalued
Valuation Signal2
Drugs Scored0.3x
rNPV / MCap Top 60%
Small Cap (rank 365 of 911)
Percentile RankTrevi Therapeutics, Inc. carries a moderate pipeline score (42/100), with $775M risk-adjusted pipeline value, led by NAL in Idiopathic Pulmonary Fibrosis (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NAL Small molecule | Idiopathic Pulmonary Fibrosis | Phase 3 | NCT04030026 | 58% | $525M | COMPLETED | 523 | - | - | May 27, 2022 | LOW_RISK | May 29, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Haduvio | chronic cough associated with idiopathic pulmonary fibrosis and other conditions | — | 2026-06-17 | statistically significant reduction in cough frequency | Trevi Therapeutics Announces Upcoming June and July Event Schedule Read More | |
Haduvio | chronic cough associated with idiopathic pulmonary fibrosis and other conditions | — | 2026-06-17 | statistically significant reduction in cough frequency | Trevi Therapeutics Announces Upcoming June and July Event Schedule Read More | |
Haduvio | chronic cough associated with idiopathic pulmonary fibrosis and other conditions | — | 2026-06-17 | statistically significant reduction in cough frequency | Trevi Therapeutics Announces Upcoming June and July Event Schedule Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in TRVI
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
TRVI Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
TRVI▲ +6.3%on this news
Trevi Therapeutics Announces Upcoming June and July Event Schedule
Trevi Therapeutics has announced its participation in several key events in June and July 2026, including the BIO International Convention and the ERS Cough Conference. The company is focused on advancing its investigational therapy, Haduvio, for chronic cough associated with idiopathic pulmonary fibrosis and other conditions. Haduvio has shown statistically significant results in reducing cough frequency in clinical trials.
Read more →TRVITrevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Trevi Therapeutics reported its Q1 2026 financial results, highlighting a successful stock offering that raised approximately $162 million. This funding extends the company's cash runway into 2030, allowing for the advancement of its lead therapy, Haduvio, for chronic cough indications. The company plans to initiate multiple clinical trials this quarter, including a Phase 3 trial for IPF-related chronic cough.
Read more →TRVITrevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference
Trevi Therapeutics has announced that it will deliver an oral presentation and present several posters at the ATS 2026 International Conference. This includes results from the Phase 2b CORAL trial evaluating nalbuphine ER for treating chronic cough in patients with idiopathic pulmonary fibrosis (IPF). The presentations will cover various analyses, indicating significant efficacy in reducing cough frequency for patients with chronic cough. This highlights the potential impact nalbuphine ER may have on the treatment landscape for patients suffering from chronic coughs associated with IPF and other conditions.
Read more →TRVITrevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026
Trevi Therapeutics will host a conference call on May 5, 2026, to discuss its financial results for Q1 2026 and provide a corporate update. The company is focused on its investigational therapy Haduvio for chronic cough associated with idiopathic pulmonary fibrosis and other conditions. Haduvio has demonstrated significant efficacy in clinical trials, targeting a high unmet medical need.
Read more →TRVITrevi Therapeutics to Participate in Upcoming May Events
Trevi Therapeutics will participate in several key events in May 2026, including an Investor and Analyst Day and the Bank of America Global Healthcare Conference. The company aims to highlight its investigational therapy Haduvio, which targets chronic cough in patients with idiopathic pulmonary fibrosis and other conditions. These events will feature senior management and key opinion leaders in the field.
Read more →TRVI▼ -5.1%on this newsshared move
Trevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
Trevi Therapeutics has successfully closed a public offering, raising approximately $173 million by selling 13,340,000 shares at $13.00 each. This includes additional shares purchased by underwriters, reflecting strong market interest. The funds will be used to advance the development of Haduvio, an investigational therapy for chronic cough associated with various lung diseases.
Read more →TRVITrevi Therapeutics Announces Proposed Public Offering of Common Stock
Trevi Therapeutics has announced a proposed public offering of $150 million in common stock to support its investigational therapy Haduvio for chronic cough. The offering includes an option for underwriters to purchase an additional $22.5 million in shares. The company is working under a shelf registration statement filed with the SEC, and the final offering terms will be disclosed later.
Read more →TRVITrevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock
Trevi Therapeutics has announced the pricing of its underwritten public offering, raising approximately $150 million by selling 11.6 million shares at $13.00 each. The offering is expected to close around April 20, 2026, pending customary conditions. The company is developing Haduvio, an investigational therapy for chronic cough, which has shown significant efficacy in trials.
Read more →TRVITrevi Therapeutics to Participate in Upcoming Events
Trevi Therapeutics, Inc. has announced its participation in several upcoming healthcare events, including the Needham Virtual Healthcare Conference and the Raymond James Biotech Innovation Symposium. Senior management, including President and CEO Jennifer Good, will represent the company during these events. Trevi's investigational therapy Haduvio is designed for chronic cough treatment in patients with idiopathic pulmonary fibrosis (IPF) and other cough-related conditions, addressing a significant unmet medical need in these populations. The company will also host an Investor and Analyst Day to further discuss their developments.
Read more →TRVITrevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the t
Trevi Therapeutics has announced its fourth quarter and full year financial results for 2025, highlighting alignment with the FDA on its Phase 3 program for treating chronic cough associated with idiopathic pulmonary fibrosis. The company plans to initiate pivotal Phase 3 trials in 2026, supported by promising Phase 2 data. Trevi ended the year with $188.3 million in cash, ensuring sufficient funds for ongoing and future clinical trials. With an escalating need for effective treatments for chronic cough, Trevi aims to address gaps in therapies for this condition.
Read more →TRVITrevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026
Trevi Therapeutics, Inc. will report its fourth quarter and year-end 2025 financial results on March 17, 2026. The conference call and webcast will provide business updates and review the company's progress. Trevi is developing Haduvio™, which has shown promise in clinical trials for treating chronic cough, particularly in patients with idiopathic pulmonary fibrosis and refractory chronic cough. The therapy, which targets a significant unmet medical need, is not currently scheduled by the U.S. DEA.
Read more →TRVI▼ -12%on this newsshared move
Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough
Trevi Therapeutics has successfully completed its End-of-Phase 2 meeting with the FDA, receiving guidance for its development program for Haduvio, an investigational therapy targeting chronic cough in patients with idiopathic pulmonary fibrosis (IPF). The company plans to conduct two pivotal Phase 3 trials, with the first trial expected to start in Q2 2026. This marks a significant step forward in addressing the unmet medical need for patients suffering from chronic cough related to IPF.
Read more →TRVI▲ +5.5%on this news
Trevi Therapeutics to Participate in Upcoming March Conferences
Trevi Therapeutics, Inc. will participate in two upcoming conferences in March 2026. The Leerink Partners 2026 Global Healthcare Conference and the Access USA Rare Disease Summit 2026 will feature key representatives discussing the investigational therapy Haduvio for chronic cough. Haduvio has shown a statistically significant reduction in cough frequency in clinical trials.
Read more →TRVITrevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Trevi Therapeutics will participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026. CEO Jennifer Good and CFO David Hastings will engage in a fireside chat and investor meetings. The company is developing Haduvio, an investigational therapy for chronic cough associated with idiopathic pulmonary fibrosis and other conditions, which has shown significant efficacy in clinical trials.
Read more →TRVITrevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA)
Trevi Therapeutics announced the publication of positive results from its Phase 2b CORAL trial of nalbuphine ER for chronic cough in patients with idiopathic pulmonary fibrosis (IPF). The trial demonstrated a statistically significant reduction in cough frequency, with over 60% of patients achieving a 50% reduction. The findings were published in JAMA, highlighting the unmet need for effective therapies in this patient population.
Read more →TRVITrevi Therapeutics Provides Strategic Updates Ahead of Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics has announced strategic updates regarding its investigational therapy Haduvio for chronic cough in patients suffering from idiopathic pulmonary fibrosis and refractory chronic cough. The company has scheduled an End-of-Phase 2 meeting with the FDA in early 2026, alongside plans to initiate a Phase 2b trial during the first half of the year. Trevi's CEO expressed optimism about advancing their clinical program amidst high unmet needs in these patient populations. However, the company also acknowledges potential uncertainties regarding the success and regulatory approval of Haduvio.
Read more →TRVITrevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer
Trevi Therapeutics has appointed David Hastings as Chief Financial Officer, effective January 6, 2026. Hastings, with over 25 years of experience in financial leadership in the biotech sector, will guide Trevi's financial strategy as the company advances its investigational therapy Haduvio for chronic cough. His previous roles include CFO positions at Arbutus and Unilife, and he has a proven track record in capital raising and commercialization.
Read more →TRVITrevi Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
Trevi Therapeutics reported its Q3 2025 financial results, highlighting a cash position of $194.9 million and plans to initiate a Phase 3 program for chronic cough in patients with idiopathic pulmonary fibrosis in 2026. The company has seen positive clinical data for its investigational therapy Haduvio, which targets chronic cough. Despite a net loss of $11.8 million, Trevi remains focused on addressing significant unmet needs in chronic cough treatments.
Read more →TRVITrevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025 Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics, Inc. will report its third quarter 2025 financial results and provide a corporate update on November 13, 2025. The company is developing Haduvio™ (oral nalbuphine ER) for treating chronic cough associated with idiopathic pulmonary fibrosis and other interstitial lung diseases. The therapy is notable as it is the first to show significant efficacy in reducing cough frequency in clinical trials. A conference call will also allow investors to gain insights into the company’s progress and future outlook.
Read more →TRVITrevi Therapeutics to Participate in Stifel 2025 Healthcare Conference
Trevi Therapeutics will participate in the Stifel 2025 Healthcare Conference on November 11, 2025. CEO Jennifer Good and CDO James Cassella will engage in a fireside chat and investor meetings. The company is developing Haduvio, an investigational therapy for chronic cough associated with idiopathic pulmonary fibrosis and other conditions, which has shown significant efficacy in clinical trials.
Read more →TRVITrevi Therapeutics Announces Oral Presentation and Abstracts at CHEST 2025 Annual Meeting
Trevi Therapeutics announced the acceptance of two abstracts for the CHEST 2025 Annual Meeting, showcasing the efficacy and safety results of nalbuphine ER for chronic cough treatment. Professor Philip Molyneaux will present key findings from the Phase 2b CORAL trial, while Associate Professor Imran Satia will discuss patient-reported outcomes from the Phase 2a RIVER trial. The meeting is scheduled for October 19-22 in Chicago.
Read more →TRVI▲ +7%on this news
Trevi Therapeutics Announces Two Posters from the Phase 2a RIVER Trial Data Will be Featured at the European Respiratory Society (ERS) Congress 2025
Trevi Therapeutics announced that data from its Phase 2a RIVER trial will be showcased in two poster presentations at the European Respiratory Society Congress 2025. The trial evaluates the efficacy and safety of Haduvio, an investigational therapy for refractory chronic cough. The congress will take place in Amsterdam from September 27 to October 1, 2025.
Read more →TRVI▼ -9.9%on this news
Trevi Therapeutics to Participate in Upcoming September Conferences
Trevi Therapeutics, Inc. will participate in several key healthcare conferences in September 2025, including the Wells Fargo Healthcare Conference and the European Respiratory Society Congress. The company is focused on developing Haduvio, an investigational therapy for chronic cough associated with idiopathic pulmonary fibrosis and refractory chronic cough. Haduvio has shown significant potential in clinical trials.
Read more →TRVITrevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates
Trevi Therapeutics reported positive topline results from its Phase 2b CORAL trial for Haduvio, aimed at treating chronic cough in patients with idiopathic pulmonary fibrosis (IPF). The company also announced a successful $115 million offering, ensuring financial stability into 2029. However, it reported a net loss of $12.3 million for the second quarter of 2025, alongside rising general and administrative expenses.
Read more →TRVITrevi Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 7, 2025 Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics, Inc. is set to report its second quarter financial results on August 7, 2025. The company is developing Haduvio™ (oral nalbuphine ER), which targets chronic cough associated with idiopathic pulmonary fibrosis (IPF) and other conditions. Haduvio has shown promising results in clinical trials as the first investigational therapy to reduce cough frequency in IPF patients. This update will be shared during a conference call and webcast by senior management.
Read more →TRVITrevi Therapeutics to Participate in Upcoming August Conferences Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics, Inc. (Nasdaq: TRVI) announced participation in upcoming biotechnology conferences, including Oppenheimer's Biotech in the Berkshires and Stifel's Biotech Summer Summit. The company is focused on the investigational therapy Haduvio™ for treating chronic cough associated with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Haduvio was noted for its potential to significantly reduce cough frequency, a major issue for patients suffering from these conditions. With no approved therapies available for chronic cough in IPF patients, Trevi aims to fill this gap in treatment options.
Read more →TRVITrevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics, Inc. (Nasdaq: TRVI) announced that its executives will attend the Leerink Partners Therapeutics Forum on July 8-9 in Boston, Massachusetts. The company is developing Haduvio™ (oral nalbuphine ER), an investigational therapy aimed at treating chronic cough associated with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Haduvio is noted for being the first investigational therapy to demonstrate a statistically significant reduction in cough frequency in clinical trials for these conditions. Currently, there are no approved therapies specifically targeting chronic cough in IPF patients.
Read more →TRVITrevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics, Inc. has announced the successful closing of its public offering, raising approximately $115.1 million through the sale of 20,010,000 shares at $5.75 each. This includes an additional 2,610,000 shares purchased by underwriters, reflecting strong investor interest. The proceeds will support further development of Haduvio™, a therapy targeting chronic cough in patients with idiopathic pulmonary fibrosis and refractory chronic cough. The offering was conducted under an effective shelf registration previously filed with the SEC.
Read more →TRVI▼ -5.8%on this newsshared move
Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics, Inc. has announced the pricing of a $100 million underwritten public offering of common stock, with shares priced at $5.75 each. The offering aims to support the development of Haduvio, an investigational therapy for chronic cough. The transaction is expected to close around June 5, 2025, pending customary conditions.
Read more →TRVI▼ -5.8%on this newsshared move
Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock New Haven, Conn.
Trevi Therapeutics announced the pricing of its underwritten public offering, aiming to raise $100 million by selling 17,400,000 shares at $5.75 each. The offering is scheduled to close on or about June 5, 2025, pending customary conditions. Trevi is focused on developing Haduvio, an investigational therapy for chronic cough in patients with idiopathic pulmonary fibrosis and refractory chronic cough.
Read more →TRVITrevi Therapeutics Announces Proposed Public Offering of Common Stock Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics, Inc. has commenced a public offering of $100 million in common stock to fund its operations and the development of Haduvio, an investigational therapy. The offering is subject to market conditions and includes a 30-day option for underwriters to purchase up to an additional $15 million of shares. As the offering proceeds, there is uncertainty regarding completion and final terms, which may be influenced by various market factors.
Read more →TRVITrevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough Haduvio met the primary endpoint with statistically-significant reductions in 24-hour cough frequency across all dose groups (108 and 54 mg BID...
Trevi Therapeutics announced positive topline results from its Phase 2b CORAL trial for Haduvio, which showed statistically significant reductions in 24-hour cough frequency in patients with idiopathic pulmonary fibrosis. All dose groups achieved notable improvements, with the 108 mg BID group showing a 60.2% reduction from baseline. The treatment was generally well-tolerated, with adverse event rates comparable to placebo. Trevi plans to seek an End-of-Phase 2 meeting with the FDA and aims to initiate Phase 3 trials in early 2026.
Read more →TRVITrevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics, Inc. announced it will host a conference call and webcast on June 2nd, 2025, to present topline results from the Phase 2b CORAL trial of its investigational therapy Haduvio for treating chronic cough in patients with idiopathic pulmonary fibrosis (IPF). With up to 85% of IPF patients suffering from chronic cough, this event signifies a crucial step in understanding Haduvio's efficacy. The company intends to propose Haduvio as the trade name for oral nalbuphine extended-release, which has shown promise in clinical trials.
Read more →TRVITrevi Therapeutics to Participate in Upcoming June Conferences Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics, Inc. has announced its participation in various conferences in June 2025 to discuss its investigational therapy, Haduvio™. The therapy aims to treat chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Notably, Haduvio has demonstrated a statistically significant reduction in cough frequency in clinical trials, making it a potentially pivotal treatment for conditions lacking approved therapies. The company's key presentations include an oral report at the American Cough Conference and poster discussions at the CPDD Annual Scientific Meeting.
Read more →TRVITrevi Therapeutics Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics has reported additional analyses from the Phase 2a RIVER trial concerning its investigational therapy Haduvio, aimed at treating refractory chronic cough. Key findings indicate a 67% reduction in objective 24-hour cough frequency. This presentation occurred at the American Thoracic Society 2025 International Conference, further validating the results. The company anticipates further insights from the upcoming Phase 2b trial in patients with idiopathic pulmonary fibrosis (IPF) who also experience chronic cough.
Read more →TRVITrevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics reported its financial results for Q1 2025, highlighting the completion of enrollment in the Phase 2b CORAL trial for Haduvio in IPF patients. The company also announced positive topline results from the Phase 2a RIVER trial in patients with refractory chronic cough. Trevi's financial position remains strong, with $103.3 million in cash, supporting ongoing development efforts.
Read more →TRVITrevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates Completed enrollment and last patient last visit in the Phase 2b CORAL trial in IPF patients with chronic cough; topline resul
Trevi Therapeutics has reported its financial results for the first quarter of 2025, highlighting successful completion of enrollment in the Phase 2b CORAL trial for its investigational therapy Haduvio, targeting chronic cough in patients with idiopathic pulmonary fibrosis (IPF). Additionally, the company announced promising results from the Phase 2a RIVER trial, indicating a statistically significant reduction in cough frequency. Trevi's solid financial standing, with cash reserves expected to last through late 2026, supports ongoing development efforts. A conference call to discuss these updates is scheduled for later today.
Read more →TRVITrevi Therapeutics to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 8, 2025 Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics, Inc. will host a conference call on May 8, 2025, to discuss financial results for Q1 2025 and provide a corporate update. The company is developing Haduvio, an investigational therapy targeting chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Haduvio is unique as it has demonstrated a statistically significant reduction in cough frequency in clinical trials. There are currently no approved treatments for chronic cough in these patient populations, emphasizing the importance of Haduvio's development.
Read more →TRVITrevi Therapeutics to Participate in Upcoming April Investor Conferences Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics, Inc. has announced its participation in several investor conferences in April 2025, highlighting the company's ongoing development of Haduvio (oral nalbuphine ER) for chronic cough treatment in patients with idiopathic pulmonary fibrosis and refractory chronic cough. The presentations will be led by senior management, including the President and CEO, Jennifer Good. Haduvio is noted as the only therapy in clinical development showing a significant reduction in chronic cough, emphasizing the unmet need in this patient population.
Read more →TRVITrevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates Announced positive topline data from the Phase 2a RIVER trial in patients with refractory chronic cough (RCC), m
Trevi Therapeutics reported strong fourth quarter and full year 2024 results, highlighting positive topline data from the Phase 2a RIVER trial for Haduvio in treating refractory chronic cough. The company also completed enrollment in the Phase 2b CORAL trial for idiopathic pulmonary fibrosis patients, with topline data expected in the second quarter of 2025. Despite increased research and development expenses, Trevi ended the year with $107.6 million in cash, ensuring a runway into the second half of 2026.
Read more →TRVITrevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March 18, 2025 Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics, Inc. has announced a conference call and webcast scheduled for March 18, 2025, to discuss its fourth quarter and annual financial results for 2024. The event will also provide a corporate update regarding the investigational therapy Haduvio, aimed at treating chronic cough in patients suffering from idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Haduvio, an oral formulation of nalbuphine, targets both central and peripheral cough reflex mechanisms and addresses a significant unmet need in this patient population.
Read more →TRVI▲ +41.2%on this newsshared move
Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough Haduvio met the primary endpoint with a statistically-significant reduction (p 0.0001) in 24-hour cough frequency with a 57% placebo-adjusted change...
Trevi Therapeutics has announced positive topline results from its Phase 2a RIVER trial of Haduvio, which showed a statistically significant 57% placebo-adjusted reduction in 24-hour cough frequency for patients with refractory chronic cough. This is a groundbreaking achievement as Haduvio is the first therapy demonstrating efficacy in this indication. Secondary outcomes were also positive, supporting the primary endpoint results. The company plans to engage with the FDA regarding the next steps in Haduvio's development, highlighting the need for effective treatments for chronic cough conditions.
Read more →TRVI▲ +41.2%on this newsshared move
Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics, Inc. announced a conference call and webcast scheduled for March 10, 2025, to discuss topline results from the Phase 2a RIVER trial evaluating Haduvio for refractory chronic cough. Haduvio, an oral formulation of nalbuphine, aims to address a critical gap in effective therapies for patients suffering from persistent cough associated with idiopathic pulmonary fibrosis and other underlying conditions. The conference call will be accessible via phone and webcast, with a replay available post-event.
Read more →TRVITrevi Therapeutics to Participate in Upcoming March Investor Conferences Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics, Inc. has announced its participation in several upcoming investor conferences in March 2025. The conferences include the TD Cowen 45th Annual Health Care Conference, the Leerink Partners Global Healthcare Conference, and the Leerink Partners Mountain Meeting, where representatives will present information about their investigational therapy Haduvio for chronic coughs associated with idiopathic pulmonary fibrosis and refractory chronic cough. This initiative demonstrates the company's focus on advancing its clinical-stage pipeline and engaging with investors.
Read more →TRVITrevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics has announced the completion of enrollment for its Phase 2b CORAL trial of Haduvio, an investigational therapy targeting chronic cough in patients with idiopathic pulmonary fibrosis (IPF). Approximately 160 patients were recruited for this double-blind, placebo-controlled study, which aims to evaluate the efficacy of three doses of Haduvio. The trial's primary efficacy endpoint focuses on measuring the change in 24-hour cough frequency after treatment. Topline results are anticipated in the first half of 2025, emphasizing the need for effective treatments in this patient population.
Read more →TRVITrevi Therapeutics to Participate in Upcoming February Investor Conferences Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics, Inc. will attend multiple investor conferences in February 2025, including the Piper Sandler Biopharma Mogul Summit and the Oppenheimer Healthcare Winter CEO & Investor Summit. The company is focused on its investigational therapy Haduvio for treating chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Haduvio, an oral formulation of nalbuphine, is designed to relieve chronic cough effectively, addressing the unmet needs in these patient populations. Trevi's management team will present at these events to raise awareness and showcase their developments in chronic cough treatments.
Read more →TRVITrevi Therapeutics Announces Company Updates Ahead of 14th Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference Last patient completed the Phase 2a RIVER trial in refractory ch
Trevi Therapeutics recently announced significant updates regarding its clinical trials and financial position ahead of the upcoming LifeSci Partners Corporate Access Event. The completion of the Phase 2a RIVER trial in refractory chronic cough marks an important milestone for the company, with topline results expected in early 2025. Additionally, the Phase 2b CORAL trial is nearing completion of enrollment, with results anticipated in the first half of 2025. A stable financial outlook is supported by an estimate of over $107 million in cash reserves.
Read more →TRVITrevi Therapeutics Announces Company Updates Ahead of 14th Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics has announced significant updates ahead of the 14th Annual LifeSci Partners Corporate Access Event. The company has completed the Phase 2a RIVER trial for refractory chronic cough and is nearing completion of the Phase 2b CORAL trial for idiopathic pulmonary fibrosis. Topline results for both trials are expected in the first half of 2025. Trevi also reported a strong cash position, indicating financial stability for ongoing development.
Read more →TRVITrevi Therapeutics Announces Pricing of $50 Million Underwritten Offering New Haven, Conn.
Trevi Therapeutics, Inc. has announced the pricing of an underwritten offering of 12,500,000 shares at $4.00 per share, totaling $50 million. The offering is anticipated to close on December 17, 2024, and includes backing from both new and existing investors. Proceeds from this financing will support the company's development of Haduvio, an investigational therapy aimed at treating chronic cough associated with idiopathic pulmonary fibrosis and refractory chronic cough. This news highlights Trevi's ongoing efforts to fund its research and development initiatives in the biopharmaceutical sector.
Read more →TRVITrevi Therapeutics Announces Pricing of $50 Million Underwritten Offering Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy, Haduvio™ (oral nalbuphine ...
Trevi Therapeutics has announced the pricing of an underwritten offering of 12.5 million shares at $4.00 each, aiming to raise $50 million. This financing will support the development of Haduvio, an investigational therapy for chronic cough. The offering is expected to close on December 17, 2024, pending customary conditions.
Read more →TRVI▲ +44.6%on this news· ran to +81% by day 3shared move
Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics announced that the sample size for its Phase 2b CORAL trial in patients with idiopathic pulmonary fibrosis and chronic cough will remain at 160 participants. The trial has now reached 75% of the targeted enrollment, with topline results anticipated in the first half of 2025. The outcome of the sample size re-estimation confirmed that the trial will proceed as initially planned, supporting the efficacy anticipated from earlier studies.
Read more →TRVITrevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics announced positive topline results from a human abuse potential study of oral nalbuphine, demonstrating significantly lower 'Drug Liking' scores at clinical doses compared to IV butorphanol. The randomized study, which included recreational drug users, also reported no serious adverse events. Trevi plans to use these results in its future drug application submissions, reinforcing nalbuphine's potential as a treatment option for chronic cough in idiopathic pulmonary fibrosis and refractory chronic cough.
Read more →TRVITrevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics, Inc. announced its participation in the Piper Sandler 36th Annual Healthcare Conference scheduled for December 4, 2024. CEO Jennifer Good and CFO Ms. Delfini will be presenting at the event and engaging in investor meetings. The company focuses on the investigational therapy Haduvio, aimed at treating chronic cough associated with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), both of which currently lack approved treatments.
Read more →TRVITrevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates Completed enrollment of the Phase 2a RIVER trial in refractory chronic cough (RCC) with topline results expected in the first
Trevi Therapeutics reported its third quarter 2024 financial results, highlighting the completion of enrollment in its Phase 2a RIVER trial for refractory chronic cough and 50% enrollment in the Phase 2b CORAL trial for chronic cough associated with idiopathic pulmonary fibrosis. The company anticipates topline results from both trials in the upcoming months, while maintaining a strong cash position of $65.5 million, expected to fund operations through the second half of 2026. Increased research and development expenses and a rising net loss, however, present challenges for the company as it advances its clinical pipeline.
Read more →TRVITrevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024 Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics, Inc. has announced a conference call and webcast scheduled for November 6, 2024, at 4:30 p.m. ET to discuss its financial results for Q3 2024 and provide a corporate update. The focus will be on Haduvio, an investigational therapy aimed at treating chronic cough from idiopathic pulmonary fibrosis and refractory chronic cough. Chronic cough significantly affects patients' quality of life, and Haduvio presents a potential solution in a market lacking approved treatments for these conditions. The therapy operates through a unique mechanism targeting opioid receptors involved in cough sensitivity.
Read more →TRVI▲ +7.4%on this news
Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics has completed enrollment for its Phase 2a RIVER trial, focusing on the investigational therapy Haduvio for refractory chronic cough. The trial, which involves around 60 adult patients, will evaluate the efficacy, safety, and tolerability of Haduvio. Positive results from previous studies in chronic cough related to idiopathic pulmonary fibrosis bolster expectations for the upcoming topline data, expected in Q1 2025. This trial addresses a significant unmet medical need, as there are currently no approved treatments for refractory chronic cough in the U.S.
Read more →TRVITrevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics, Inc. is set to participate in several upcoming investor and medical conferences. The company's investigational therapy Haduvio (oral nalbuphine ER) is aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). During the conferences, key representatives will present insights into commercial strategies and updates on the therapy's development. Haduvio, which has not yet been evaluated by regulatory authorities, could fulfill a critical need for patients with chronic cough conditions, as there are currently no approved therapies for these indications.
Read more →TRVI▼ -5.3%on this news
Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics, Inc. has achieved a significant milestone by reaching 50% enrollment in the Phase 2b CORAL trial for its investigational therapy Haduvio, aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF). Additionally, dosing for the Human Abuse Potential study has been completed, with topline results expected in December 2024. The CEO expressed optimism about Haduvio's unique dual-action mechanism that could address a critical unmet need in chronic cough treatment, a condition that currently lacks approved therapies.
Read more →TRVITrevi Therapeutics Announces Appointment of James V. Cassella, Ph.D., as Chief Development Officer Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics has appointed Dr. James V. Cassella as Chief Development Officer. Dr. Cassella, who has over 35 years of experience in drug development, will focus on advancing Haduvio, an investigational therapy for chronic cough. His leadership is expected to play a crucial role in the upcoming pivotal development program and regulatory submission for Haduvio.
Read more →TRVITrevi Therapeutics Announces Appointment of James V. Cassella, Ph.D., as Chief Development Officer New Haven, Conn.
Trevi Therapeutics has appointed James V. Cassella, Ph.D., as the new Chief Development Officer, replacing Dr. David Clark, who will remain as a consultant. Dr. Cassella brings over 35 years of experience in drug development, particularly in CNS therapies, and has a history of leading key regulatory approvals. His role will focus on advancing Haduvio, an investigational therapy aimed at chronic cough in idiopathic pulmonary fibrosis and refractory chronic cough, with significant upcoming clinical milestones. The company remains committed to addressing the high unmet medical need in these conditions.
Read more →TRVITrevi Therapeutics Announces Additional Analyses of Cough Relief Time from Ph2a CANAL Trial Accepted for Oral Presentation at CHEST 2024 Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics announced that results from its Phase 2a CANAL trial will be presented at CHEST 2024. The analysis focuses on cough relief in patients with idiopathic pulmonary fibrosis treated with nalbuphine ER. The data suggest significant improvements in cough relief time, intensity, and duration compared to placebo among participants. However, some adverse events were noted, including nausea and dizziness. The findings highlight the potential of Haduvio as a new treatment for chronic cough in patients with IPF.
Read more →TRVITrevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024 Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics announced that data from its Phase 2a CANAL trial will be presented at the European Respiratory Society Congress 2024. The study focuses on the correlation between the objective cough count and patient-reported improvements with Haduvio (oral nalbuphine ER) among patients with idiopathic pulmonary fibrosis. The oral presentation is scheduled for September 8. This research highlights the significance of patient-reported outcomes in assessing treatment efficacy for chronic cough, a condition currently lacking approved therapeutic options.
Read more →TRVITrevi Therapeutics to Participate in September Investor and Medical Conferences Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics, Inc. will participate in several key investor and medical conferences in September 2024 to present its investigational therapy Haduvio, aimed at treating chronic cough related to idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Notable events include the Wells Fargo Healthcare Conference and the European Respiratory Society Congress, where Trevi's management will discuss the therapy's potential benefits. Haduvio has not yet been evaluated by regulatory authorities, but it targets a significant healthcare gap due to the lack of approved treatments for these conditions.
Read more →TRVI▲ +8.1%on this news
Trevi Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates Reaffirming Clinical Trial Guidance     Topline results expected in the fourth quarter of 2024 in the Phase 2a
Trevi Therapeutics has released its financial results for the second quarter of 2024 alongside an update on its clinical trials. The company is nearing completion of enrollment for its Phase 2a RIVER trial, with results anticipated in Q4 2024. Additionally, the Phase 2b CORAL trial is set to reach a sample size re-estimation milestone during the same period. Despite a reported net loss for the quarter, Trevi maintains a strong cash position to support ongoing clinical development efforts.
Read more →TRVI▲ +8.1%on this news
Trevi Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates Reaffirming Clinical Trial Guidance Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics reported its second quarter 2024 financial results, highlighting strong enrollment in its Phase 2a RIVER trial for refractory chronic cough, with topline results expected in Q4 2024. The company also anticipates a sample size re-estimation in its Phase 2b CORAL trial. Despite a net loss of $12.4 million, Trevi maintains a solid cash position, projecting a runway into 2026.
Read more →TRVITrevi Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 8, 2024 Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics, Inc. will report its second quarter 2024 financial results and provide a corporate update on August 8, 2024. The company is developing Haduvio, an investigational therapy for chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). The conference call will include a financial review and updates on the company's progress in the clinical stage. There are currently no approved therapies for chronic cough in IPF or RCC, highlighting the potential importance of Haduvio.
Read more →TRVI▼ -7.3%on this news
Trevi Therapeutics to Participate in Upcoming Investor and Healthcare Events Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics, Inc. has announced its participation in several upcoming investor and healthcare events, emphasizing their investigational therapy Haduvio™ for chronic cough. Notably, two abstracts regarding ongoing clinical trials for Haduvio have been accepted for presentation at the Thirteenth London International Cough Symposium. The company aims to highlight its advancements in treating chronic cough associated with idiopathic pulmonary fibrosis and refractory chronic cough, conditions currently lacking approved therapies. Key representatives will attend multiple conferences in July and August to discuss these developments and engage with stakeholders.
Read more →TRVI▲ +10.6%on this news
Trevi Therapeutics to Participate in Upcoming Conferences Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics, Inc. is preparing to participate in a series of conferences in May and June 2024, presenting its investigational therapy Haduvio™ for chronic cough. Key events include the Citizens JMP Life Sciences Conference and the ATS 2024 International Conference, where findings on Haduvio's effects will be discussed. The company aims to highlight the potential of Haduvio in treating conditions like idiopathic pulmonary fibrosis and refractory chronic cough. As there are no existing approved therapies for these conditions, Trevi's presence at these conferences represents an important step in advancing its research and development efforts.
Read more →TRVITrevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates     Reaffirms guidance for the Phase 2a RIVER trial in refractory chronic cough and Human Abuse Potential (HAP)
Trevi Therapeutics reported its financial results for Q1 2024, highlighting ongoing clinical trials and future expectations. The company reaffirmed its guidance for the Phase 2a RIVER trial in refractory chronic cough and outlined the timeline for topline data in late 2024. Additionally, Trevi announced the clearance of an IND for a Phase 1b trial to evaluate respiratory physiology in patients with idiopathic pulmonary fibrosis. Despite a net loss in the quarter, the company maintains a strong cash position to support its operational plans into 2026.
Read more →TRVITrevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates Reaffirms guidance for the Phase 2a RIVER trial in refractory chronic cough and Human Abuse Potential (HAP) Study with topline data for each expected ...
Trevi Therapeutics reported its financial results for Q1 2024, highlighting progress in its clinical trials for Haduvio, an investigational therapy for chronic cough. The company reaffirmed guidance for the Phase 2a RIVER trial and the Human Abuse Potential study, with topline data expected in the second half of 2024. Despite a net loss of $10.9 million, Trevi maintains a strong cash position, projected to last into 2026.
Read more →TRVITrevi Therapeutics to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 7, 2024 Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics, Inc. will report its financial results for the first quarter of 2024 and provide a corporate update on May 7, 2024. The company is developing Haduvio, an investigational therapy aimed at treating chronic cough associated with idiopathic pulmonary fibrosis and refractory chronic cough. The lack of approved therapies for these conditions highlights the potential significance of Haduvio in the market. The event will include a live conference call and webcast accessible to participants.
Read more →TRVI▼ -8.1%on this news
Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics, Inc. announced that data from its Phase 2 CANAL trial will be presented at the American Thoracic Society International Conference in May 2024. The study focuses on the effects of Haduvio (oral nalbuphine ER) on chronic cough in patients with idiopathic pulmonary fibrosis (IPF). The presentation, scheduled for May 19, will be conducted by Professor Jacky Smith from the University of Manchester. This development highlights the investigational therapy's potential in addressing chronic cough, an area with significant patient needs and no existing approved treatments.
Read more →TRVITrevi Therapeutics to Participate in Upcoming April Events Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics, Inc. (Nasdaq: TRVI) will participate in major upcoming events, including the Needham Virtual Healthcare Conference and the European Pulmonary Fibrosis Foundation Patient Summit. During these conferences, Trevi's management, including their President and CEO, will discuss their investigational therapy Haduvio for chronic cough associated with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Haduvio may benefit patients suffering from these conditions, as current treatment options are limited.
Read more →TRVITrevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics has appointed Dr. Margaret Garin as Vice President of Clinical Development to lead the advancement of their investigational therapy, Haduvio, aimed at treating chronic cough related to idiopathic pulmonary fibrosis and refractory chronic cough. Dr. Garin brings over 14 years of experience in the industry, including a successful track record in managing clinical trials. This appointment comes at a crucial time as there are currently no approved therapies for chronic cough in these indications, highlighting the potential impact of Haduvio in addressing an urgent unmet medical need.
Read more →TRVITrevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics reported its financial results for Q4 and the full year 2023, highlighting progress in clinical trials for its investigational therapy Haduvio. The Phase 2a RIVER trial for refractory chronic cough (RCC) and the Phase 2b CORAL trial for chronic cough in idiopathic pulmonary fibrosis (IPF) are both underway, with topline data expected in 2024. The company ended the year with $83 million in cash, indicating a solid financial position.
Read more →TRVITrevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates     Reaffirms guidance for the Phase 2a RIVER trial of Haduvio in RCC patients with topline data e
Trevi Therapeutics has reported its financial results for Q4 and the full year of 2023, highlighting significant business developments. The company reaffirmed guidance for topline data from the Phase 2a RIVER trial and ongoing trials for chronic cough, with enrollment progressing well. Despite some financial losses, Trevi maintains a robust cash position, suggesting it can support ongoing research and development efforts into 2024.
Read more →TRVITrevi Therapeutics to Report Q4 and Year End 2023 Financial Results and Provide a Corporate Update on March 20, 2024 Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics, Inc. will host a conference call and webcast on March 20, 2024, to report its Q4 and year-end 2023 financial results and provide a corporate update. The company is focused on Haduvio, an investigational therapy aimed at treating chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Haduvio has the potential to significantly impact the quality of life for patients suffering from these conditions, as existing treatment options are limited and provide inadequate relief.
Read more →TRVI▲ +5.8%on this news
Trevi Therapeutics to Participate in Upcoming March Events Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics, Inc. is set to participate in several health conferences in March 2024 to showcase its investigational therapy Haduvio for chronic cough. The events include the TD Cowen Annual Health Care Conference, Connecticut Rare Disease Forum, Leerink Partners Global Biopharma Conference, and BIO-Europe Spring. Haduvio, designed to address chronic cough in idiopathic pulmonary fibrosis and refractory chronic cough, is at the forefront of innovation in an area with no approved treatments. The company aims to broaden Haduvio's applications and engage with industry peers during these key events.
Read more →TRVITrevi Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics, Inc. will showcase its investigational therapy Haduvio at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 14, 2024. CEO Jennifer Good and CFO Lisa Delfini will present and hold investor meetings during the virtual event. Haduvio aims to treat chronic cough associated with idiopathic pulmonary fibrosis and refractory chronic cough, targeting a significant unmet need in these conditions. The drug's development highlights Trevi's commitment to providing potential solutions for patients who currently have no approved therapies.
Read more →TRVI▲ +5.3%on this news
Trevi Therapeutics Provides Business Updates Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics, a clinical-stage biopharma company, has announced updates on its investigational therapy Haduvio for chronic cough associated with idiopathic pulmonary fibrosis and refractory chronic cough. The company is set to attend the 13th Annual LifeSci Partners Corporate Access Event in January to discuss ongoing trials. Trevi has received regulatory approval to begin its Phase 2b trial in eight out of ten countries, expecting topline results by mid-2025. Additionally, the Human Abuse Potential study is slated to begin dosing in January 2024 with results anticipated later that year.
Read more →TRVITrevi Therapeutics Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio™ for Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF) Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics has initiated its Phase 2b CORAL clinical trial for Haduvio, targeting chronic cough in idiopathic pulmonary fibrosis (IPF) patients. Approximately 160 subjects will be enrolled to study three doses of Haduvio against placebo, following positive results from the Phase 2a CANAL trial, which showed a notable reduction in cough frequency. The trial aims to assess the change in 24-hour cough frequency and includes secondary endpoints related to patients' quality of life. Current treatment options for chronic cough in IPF are limited, highlighting the importance of this trial.
Read more →TRVITrevi Therapeutics Announces Third Quarter 2023 Financial Results and Provides Business Update Initiated Phase 2a RIVER trial of Haduvio in refractory chronic cough (RCC) patients and expect topline data in the second ha
Trevi Therapeutics has announced its financial results for Q3 2023, highlighting the initiation of the Phase 2a RIVER trial for Haduvio in patients with refractory chronic cough. The company expects to report topline data from this trial in the second half of 2024. Additionally, Trevi plans to commence a Phase 2b dose-ranging trial for chronic cough associated with idiopathic pulmonary fibrosis by the end of 2023. Despite a net loss reported for the quarter, Trevi maintains a healthy cash position of $88.9 million to support upcoming clinical programs.
Read more →TRVITrevi Therapeutics Announces Third Quarter 2023 Financial Results and Provides Business Update Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics announced its Q3 2023 financial results, highlighting the initiation of the Phase 2a RIVER trial for Haduvio in refractory chronic cough patients, with topline data expected in late 2024. The company also plans to start a Phase 2b trial for chronic cough in idiopathic pulmonary fibrosis by the end of 2023. Despite a net loss of $7.7 million, Trevi maintains a strong cash position of $88.9 million.
Read more →TRVI▼ -5.7%on this news
Trevi Therapeutics Announces the Initiation of its Phase 2a RIVER Clinical Trial of Haduvio™ for Refractory Chronic Cough Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics has commenced its Phase 2a RIVER clinical trial focusing on Haduvio, an investigational therapy for refractory chronic cough (RCC). This trial aims to evaluate the safety and efficacy of Haduvio in a population suffering from this persistent condition, which affects a significant portion of adults globally. Topline results are anticipated in the second half of 2024. Given the lack of approved treatments for RCC, the trial may address a critical unmet medical need.
Read more →TRVITrevi Therapeutics to Report Q3 2023 Financial Results and Provide a Corporate Update on November 9, 2023 Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics, Inc. has announced that it will report its Q3 2023 financial results on November 9, 2023. The company is focused on the development of its investigational therapy Haduvio, aimed at treating chronic cough associated with idiopathic pulmonary fibrosis and other conditions. A conference call and live audio webcast will provide updates on the company's performance and developments in Haduvio's pathway. This event highlights the ongoing challenges and opportunities in treating chronic cough, where few therapies currently exist.
Read more →TRVITrevi Therapeutics Announces Results from Phase 2b/3 PRISM Open-Label Extension Study of Haduvio™ in Prurigo Nodularis Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics announced positive results from its Phase 2b/3 PRISM study extension of Haduvio for prurigo nodularis, showing continued reduction in itch severity among participants over 52 weeks. The long-term safety profile was amongst the key findings presented at the EADV Congress 2023, indicating that treatment was generally well tolerated. Adverse events were reported, leading to some participants discontinuing the study, but the overall data supports further development plans. Trevi intends to discuss these results with the FDA as part of their ongoing clinical program.
Read more →TRVITrevi Therapeutics to Participate in Upcoming September Events Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics, Inc. announced its participation in several upcoming industry events, including the European Respiratory Society International Congress and the Cantor Global Healthcare Conference. The company is focused on its investigational therapy Haduvio™ for treating chronic cough in patients with idiopathic pulmonary fibrosis and other indications. This participation aims to raise awareness about Haduvio™, which has potential benefits for patients lacking effective treatments. The company emphasizes the significance of chronic cough and its impact on quality of life.
Read more →TRVITrevi Therapeutics Announces Second Quarter 2023 Financial Results and Provides Business Update Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics announced its financial results for Q2 2023, reporting a net loss of $7.1 million. The company is on track to initiate three clinical trials for chronic cough later this year, following positive data from the Phase 2 CANAL trial. However, a shortage of a key comparator drug may delay year-end results.
Read more →TRVITrevi Therapeutics Announces Second Quarter 2023 Financial Results and Provides Business Update Plans to initiate three clinical studies in chronic cough indications for later this year remain on track Data from Phase 2
Trevi Therapeutics recently announced its financial results for Q2 2023 and outlined plans to initiate three clinical studies for chronic cough indications later this year. The publication of positive data from the Phase 2 CANAL trial has generated significant interest among the medical community. However, the company faces a challenge due to a shortage of the comparator drug IV butorphanol, which may delay results. Despite these challenges, Trevi holds a strong cash position as it continues to push forward with its developmental plans.
Read more →TRVITrevi Therapeutics to Report Q2 2023 Financial Results and Provide a Corporate Update on August 10, 2023 Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics, a clinical-stage biopharmaceutical company, will host a conference call and webcast on August 10, 2023, at 4:30 p.m. ET to discuss their Q2 2023 financial results and provide a corporate update. The company is developing Haduvio™, an oral formulation of nalbuphine ER, aimed at treating chronic cough related to idiopathic pulmonary fibrosis and other conditions. Haduvio is distinguished as a dual-opioid receptor agent with the potential for a beneficial effect on chronic cough treatment.
Read more →TRVITrevi Therapeutics to Participate in Upcoming August Events Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics, Inc. is set to participate in key industry events in August, including the BTIG Virtual Biotechnology Conference and the Stifel Biotech Executive Summit. Senior management, including CEO Jennifer Good, will provide insights into the company's investigational therapy Haduvio™. Haduvio™ aims to address chronic cough associated with idiopathic pulmonary fibrosis and other conditions. The therapy represents a promising advancement in a field lacking approved treatment options.
Read more →TRVITrevi Therapeutics to Participate in Upcoming July Investor Events Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics, Inc. has announced that its senior management will participate in several investor events in July, including the SVB Securities Therapeutics Forum and Oppenheimer's Montauk Life Sciences Summit. The company is developing Haduvio, an investigational therapy aimed at treating chronic cough associated with idiopathic pulmonary fibrosis and other indications. Haduvio, a dual opioid receptor modulator, has the potential to address a significant unmet need as there are currently no approved treatments for this condition. Trevi aims to propose Haduvio as the trade name for its oral nalbuphine formulation.
Read more →TRVI▼ -5%on this news
Trevi Therapeutics Announces Publication of Positive Data from the CANAL Trial in IPF Chronic Cough in NEJM Evidence Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics announced positive results from the Phase 2 CANAL trial of Haduvio (oral nalbuphine ER) for chronic cough in idiopathic pulmonary fibrosis (IPF). The trial demonstrated a significant reduction in cough frequency, and the results were published in NEJM Evidence. The safety profile of Haduvio during the trial was generally consistent with previous studies, with no treatment-related serious adverse events reported. This publication is crucial for patients suffering from IPF-related cough, as there are currently no approved therapies for this condition in the U.S.
Read more →TRVITrevi Therapeutics Announces First Quarter 2023 Financial Results and Provides Business Update Initiating three clinical studies in chronic cough indications later this year Received Notice of Allowance for key U.S. pate
Trevi Therapeutics has reported its first quarter 2023 financial results and announced plans to initiate three clinical trials for chronic cough indications later this year. The company received a Notice of Allowance for a key U.S. patent covering the use of oral nalbuphine ER in the treatment of chronic cough linked to idiopathic pulmonary fibrosis (IPF). Management indicated that their clinical development plans are on track, including the completion of important studies. The company ended the quarter with $111.3 million in cash and equivalents to support its ongoing and planned clinical trials.
Read more →TRVITrevi Therapeutics to Present at Upcoming Yale Innovation Summit 2023 Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics, Inc. is set to present at the Yale Innovation Summit on June 1, 2023. The company will discuss its investigational therapy Haduvio, aimed at treating chronic cough in conditions such as idiopathic pulmonary fibrosis. Key insights on the therapy's mechanism and commercial potential will be shared alongside expert Dr. Peter Dicpinigaitis. The presentation highlights Trevi's commitment to addressing the unmet needs in chronic cough treatment.
Read more →TRVITrevi Therapeutics to Report Q1 2023 Financial Results and Provide a Corporate Update on May 11, 2023 Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics, Inc. will report its Q1 2023 financial results on May 11, 2023, during a conference call and webcast. The company is focused on its investigational therapy, Haduvio, aimed at treating chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and prurigo nodularis. This event will provide a corporate update and an overview of the company's financial performance for the first quarter. Interested parties can access the conference call via phone or live audio webcast from Trevi's website.
Read more →TRVITrevi Therapeutics Announces Two Presentations on the Phase 2 CANAL Data at the ATS 2023 International Conference Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics, Inc. has announced the presentation of two scientific abstracts related to its investigational therapy Haduvio at the ATS 2023 International Conference. These presentations will showcase results from the Phase 2 CANAL trial focused on chronic cough in patients with idiopathic pulmonary fibrosis (IPF). Both presentations will be made by Dr. Toby Maher on May 22, highlighting the therapy’s efficacy and impact on patient-reported outcomes. This event marks a key moment for Trevi as it seeks to address a significant unmet medical need in this patient population.
Read more →TRVITrevi Therapeutics to Participate in Upcoming May Investor Events Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics, Inc. (Nasdaq: TRVI) announced its participation in several investor events in May 2023, including the Aegis Virtual Conference and the American Thoracic Society's Respiratory Innovation Summit. Senior management, including CEO Jennifer Good, will present insights into their investigational therapy Haduvio, targeting chronic cough in conditions like idiopathic pulmonary fibrosis. The engagements provide a platform for Trevi to showcase its products and foster relationships with investors and analysts.
Read more →TRVITrevi Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics, Inc. will participate in the 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023. Key executives, including President Jennifer Good, will engage in a fireside chat and hold investor meetings. The company is developing Haduvio, an investigational therapy for chronic cough and prurigo nodularis, indicating its active role in addressing unmet medical needs. A live webcast will be available for interested stakeholders.
Read more →TRVITrevi Therapeutics Announces Fourth Quarter and Year End 2022 Financial Results and Provides Business Update Multiple trial initiations planned for 2023 to progress Haduvio in chronic cough indications Management to host
Trevi Therapeutics reported its fourth quarter and full-year 2022 financial results, highlighting a strong cash position of $120.5 million and plans for multiple trial initiations in 2023 for its investigational therapy, Haduvio, targeting chronic cough indications. The company aims to conduct several studies, including a Phase 2b trial in idiopathic pulmonary fibrosis patients and a Phase 2a study in refractory chronic cough. Despite reporting a net loss, there was an overall improvement compared to 2021, and management remains optimistic about future developments and FDA discussions.
Read more →TRVI▼ -9.2%on this news· ran to -22% by day 1
Trevi Therapeutics to Report Q4 and Year End 2022 Financial Results and Provide a Corporate Update on March 16, 2023 Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics, Inc. will report its Q4 and year-end financial results for 2022 on March 16, 2023. The company, focused on developing Haduvio for chronic cough and prurigo nodularis, will host a conference call and audio webcast for investors. This meeting aims to provide corporate updates and review financial outcomes. Haduvio, an oral formulation of nalbuphine, targets chronic cough linked to idiopathic pulmonary fibrosis and is not yet evaluated by regulatory authorities.
Read more →TRVITrevi Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering Use of Haduvio™ (nalbuphine ER) for the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics has received a notice of allowance from the USPTO for its patent application concerning the use of nalbuphine ER in treating chronic cough in idiopathic pulmonary fibrosis (IPF). This patent, expected to be listable in the Orange Book, will provide protection until 2039. Chronic cough is a critical symptom for IPF patients, which currently lack effective therapies. Trevi aims to fortify its patent portfolio as it gathers more clinical data to support its investigational therapy, Haduvio.
Read more →TRVITrevi Therapeutics to Participate in Upcoming March Conferences Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics, Inc. has announced its participation in a series of upcoming conferences in March, including the Frazier/Fenwick Winter Investor Event and the Oppenheimer 33rd Annual Healthcare Conference. The company aims to showcase its investigational therapy Haduvio for chronic cough treatments, following positive results from the Phase 2 CANAL trial. Trevi is committed to further exploring treatments for chronic cough associated with idiopathic pulmonary fibrosis and other related conditions.
Read more →TRVITrevi Therapeutics to Present at the Emerging Growth Conference on February 22, 2023 Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics, Inc. will present at the Emerging Growth Conference on February 22, 2023, at 10:50 a.m. ET. The presentation will feature senior leadership addressing shareholders and the investment community. Trevi is developing Haduvio, an investigational therapy for chronic cough associated with idiopathic pulmonary fibrosis and other indications. The company recently reported positive results from its Phase 2 trial, focusing future development on chronic cough conditions.
Read more →TRVI▲ +20.2%on this news
Trevi Therapeutics to Present and Participate in Upcoming February Conferences Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics, Inc. will participate in two upcoming investor conferences in February 2023. The first is the BIO CEO & Investor Conference from February 6-9, where they will present on February 7. They will also present at the SVB Securities Global Biopharma Conference from February 13-16, with a corporate presentation scheduled for February 14. The company is developing the investigational therapy Haduvio™ for chronic cough in adults with idiopathic pulmonary fibrosis and other conditions.
Read more →TRVI▲ +8.5%on this news
Trevi Therapeutics Provides Business Update Ahead of Upcoming Conferences Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics, Inc. has provided a business update highlighting its achievements over the past year and future plans. The company is focusing on the clinical development of its therapy Haduvio for treating chronic cough associated with idiopathic pulmonary fibrosis and other conditions. Upcoming meetings and potential studies are planned as part of their strategy moving forward. Despite their advancements, the company acknowledges the inherent uncertainties and risks associated with clinical trials and regulatory approvals.
Read more →TRVITrevi Therapeutics to Present and Participate in Upcoming Conferences in San Francisco During the 41st Annual J.P. Morgan Health Care Conference Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Biotech Showcase 2023, January 9-11 – Corporate presentation on Tuesday, January 10 , at 3:00 p.m. PT 12 th Annual LifeSci Partners Corporate Access Event, January 9-11 NEW HAVEN, Conn. , Dec. 19 , 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI ), a clinical-stage
Read more →TRVITrevi Therapeutics Appoints Pharma Industry Veteran as Chief Medical Officer Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
David Clark , MD, MRCP, will lead the continued development of Haduvio™ NEW HAVEN, Conn. , Nov. 14, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI ), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for
Read more →TRVITrevi Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update Management to host a conference call and webcast today at 4:30 p.m. EDT New Haven, Conn.
Trevi Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update Management to host a conference call and webcast today at 4:30 p.m. EDT New Haven, Conn., November 10, 2022 - Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutic
Read more →TRVITrevi Therapeutics to Participate at the Stifel 2022 Healthcare Conference Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine...
Fireside chat will be held on Wednesday, November 16, 2022 , from 3:35 p.m. to 4:05 p.m. EDT NEW HAVEN, Conn. , Nov. 8, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI ), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral
Read more →TRVITrevi Therapeutics to Report Q3 2022 Financial Results and Provide a Corporate Update on November 10, 2022 Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine...
Conference call and webcast to be held at 4:30 p.m. EDT NEW HAVEN, Conn. , Nov. 3, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI ), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of s
Read more →TRVITrevi Therapeutics to Present Final Data from Phase 2 Trial of Oral Nalbuphine Extended Release for Chronic Cough in IPF at BTS' Winter Meeting Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine...
Data from full set of subjects was statistically significant for the primary efficacy endpoint (p<0.0001) Key secondary patient and clinician-reported outcomes supported positive primary endpoint NEW HAVEN, Conn. , Oct. 27, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq:
Read more →TRVI▼ -9.6%on this news
Trevi Therapeutics Announces Pricing of $55 Million Public Offering New Haven, Conn.
Trevi Therapeutics Announces Pricing of $55 Million Public Offering New Haven, Conn., September 23, 2022 Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy, Haduvio (oral nalbuphine ER) for the treatment of
Read more →TRVI▼ -12.2%on this newsshared move
Trevi Therapeutics Announces Proposed Public Offering Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy, Haduvio™ (oral nalbuphine...
NEW HAVEN, Conn. , Sept. 22, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI ), a clinical-stage biopharmaceutical company developing an investigational therapy, Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibro
Read more →TRVI▼ -6.1%on this news· ran to -41% by day 3shared move
Corporate Presentation September 2022 Forward Looking Statement Disclaimer Statements contained in this presentation and oral statements made regarding the subject of this presentation regarding matters that are not hist
Corporate Presentation September 2022 Forward Looking Statement Disclaimer Statements contained in this presentation and oral statements made regarding the subject of this presentation regarding matters that are not historical facts are "forward-looking statements" within the me
Read more →TRVI▼ -6.1%on this news· ran to -41% by day 3shared move
Trevi Therapeutics Announces Positive Data from Full Set of Subjects in Phase 2 CANAL Trial of Haduvio™ in the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy, Haduvio™ (oral nalbuphine...
Data from full set of subjects was statistically significant for the primary efficacy endpoint of daytime cough frequency reduction (p<0.0001) Magnitude of daytime and 24hr cough frequency reduction were consistent Key secondary endpoints on patient and clinician reported outco
Read more →TRVITrevi Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine...
Presentation will be held on Monday, September 12, 2022 , from 10:30 a.m. to 11:00 a.m. EDT NEW HAVEN, Conn. , Sept. 7, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI ), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral
Read more →TRVI▼ -9.5%on this news
Trevi Therapeutics to Host Virtual R&D Day on September 19, 2022 Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine...
The event will feature presentations from experts Dr. Peter Dicpinigaitis , MD, and Dr. Brian Kim , MD, MTR Virtual event to be held on Monday, September 19 th from 10 AM – 12:30 PM ET NEW HAVEN, Conn. , Aug. 30, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI ), a
Read more →TRVITrevi Therapeutics Announces Multiple Late-Breaking Abstracts Accepted for Presentation at Upcoming Medical Conferences on Analysis of Oral Nalbuphine Extended Release Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine...
Late-breaker abstract accepted for oral presentation on the interim analysis of cough in patients with idiopathic pulmonary fibrosis (IPF) at the upcoming European Respiratory Society International Congress 2022, Barcelona, Spain , September 4-6 Late-breaker abstract accepted fo
Read more →TRVITrevi Therapeutics Announces Second Quarter 2022 Financial Results and Business Update Reported positive results from the Phase 2b/3 PRISM trial of Haduvio in the treatment of Prurigo Nodularis Completed a $55 million pr
Trevi Therapeutics Announces Second Quarter 2022 Financial Results and Business Update Reported positive results from the Phase 2b/3 PRISM trial of Haduvio in the treatment of Prurigo Nodularis Completed a $55 million private placement Data from the full set of subjects in the
Read more →TRVITrevi Therapeutics to Present at Upcoming August Conferences Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine...
NEW HAVEN, Conn. , Aug. 9, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ: TRVI ), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio ™ (oral nalbuphine ER) for the treatment of prurigo nodularis (PN) and chronic cough in adults with i
Read more →TRVI▲ +5.2%on this news· ran to +19% by day 3shared move
Trevi Therapeutics to Report Q2 2022 Financial Results and Provide a Corporate Update on August 11, 2022 Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine...
Conference call and webcast to be held at 4:30 p.m. EDT NEW HAVEN, Conn. , Aug. 4, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI ), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of p
Read more →TRVITrevi Therapeutics to Attend the Twelfth London International Cough Symposium (12th LICS) Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine...
NEW HAVEN, Conn. , July 7, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI ), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine ER) for prurigo nodularis and chronic cough in idiopathic pulmonary fibrosis (IPF),
Read more →TRVI▲ +21.3%on this news· ran to +65% by day 3
Trevi Therapeutics Reports Positive Results from the Ph2b/3 PRISM Trial of Haduvio™ in the Treatment of Prurigo Nodularis Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine...
Haduvio (oral nalbuphine ER) demonstrated statistically significant results on the primary efficacy endpoint as measured by a 4-point reduction in the Worst Itch – Numerical Rating Scale (WI-NRS) (p=0.0157) The trial also met key secondary endpoints, with a safety profile consis
Read more →TRVITrevi Therapeutics to Present and Participate in Partnership Meetings at Upcoming 2022 BIO International Convention Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER)...
NEW HAVEN, Conn. , June 7, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI ), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER) for pruritus in prurigo nodularis (PN) and chronic cough in idiopathic pulmonary fib
Read more →TRVITrevi Therapeutics Announces First Quarter 2022 Financial Results and Business Update Accelerated planning for next phase of development of Haduvio for the treatment of chronic cough in IPF based on results from statisti
Trevi Therapeutics Announces First Quarter 2022 Financial Results and Business Update Accelerated planning for next phase of development of Haduvio for the treatment of chronic cough in IPF based on results from statistically significant interim analysis of Phase 2 CANAL Trial
Read more →TRVI▼ -5.7%on this news
Trevi Therapeutics to Report Q1 2022 Financial Results and Provide a Corporate Update on May 12, 2022 Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER)...
Conference Call and Webcast to be Held at 4:30 p.m. EDT NEW HAVEN, Conn. , May 5, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI ), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER) for pruritus in prurigo nodu
Read more →TRVITrevi Therapeutics to Present at Upcoming May Meetings Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER)...
NEW HAVEN, Conn. , May 3, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI ), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER) for pruritus in prurigo nodularis (PN) and chronic cough in idiopathic pulmonary fibr
Read more →TRVITrevi Therapeutics to Participate at 21st Annual Needham Virtual Healthcare Conference Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER)...
UPDATE: Fireside chat will be held on Tuesday, April 12, 2022 , from 10:15 a.m. to 10:55 a.m. EDT NEW HAVEN, Conn. , April 11, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI ), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™
Read more →TRVI▲ +56.8%on this newsshared move
Trevi Therapeutics Announces $55 Million Private Placement Priced At-the-Market Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER)...
Proceeds To Fund the Development of Haduvio for Chronic Cough in Idiopathic Pulmonary Fibrosis NEW HAVEN, Conn. , April 7, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI ), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (na
Read more →TRVI▲ +5.6%on this news· ran to +66% by day 1shared move
SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this Agreement ) is dated as of
SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this Agreement ) is dated as of April 6, 2022, between Trevi Therapeutics, Inc., a Delaware corporation (the Company ), and each purchaser identified on the Schedule of Purchasers attached hereto as Exhibit A (ea
Read more →TRVI▼ -8.6%on this news· ran to +36% by day 3shared move
Trevi Therapeutics to Participate at 21st Annual Needham Virtual Healthcare Conference Trevi Therapeutics, Inc. (Nasdaq: TRVI) is a clinical-stage biopharmaceutical company developing an investigational oral therapy Haduvio™ (nalbuphine ...
Fireside chat will be held on Tuesday, April 12, 2022 , from 8:00 a.m. to 8:40 a.m. EDT NEW HAVEN, Conn. , April 5, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI ) is a clinical-stage biopharmaceutical company developing an investigational oral therapy Haduvio™ (na
Read more →TRVI▲ +14.4%on this news
Trevi Therapeutics Hosting Key Opinion Leader Webinar on the Seriousness of Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF) Trevi Therapeutics, Inc. (Nasdaq: TRVI) is a clinical-stage biopharmaceutical company developing an investigational oral therapy Haduvio™ (nalbuphine ...
Webinar will be held on Wednesday, March 30, 2022 , from 8:00 a.m. to 9:00 a.m. EDT NEW HAVEN, Conn. , March 22, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI ) is a clinical-stage biopharmaceutical company developing an investigational oral therapy Haduvio™ (nalbu
Read more →TRVITrevi Therapeutics Announces Fourth Quarter and Year End 2021 Financial Results and Business Update Interim Analysis in Phase 2 CANAL Trial Showed Primary Efficacy Endpoint of Cough Reduction in Idiopathic Pulmonary Fibr
Trevi Therapeutics Announces Fourth Quarter and Year End 2021 Financial Results and Business Update Interim Analysis in Phase 2 CANAL Trial Showed Primary Efficacy Endpoint of Cough Reduction in Idiopathic Pulmonary Fibrosis was Highly Statistically Significant (p-value less tha
Read more →TRVI▲ +10.6%on this news· ran to +27% by day 3shared move
Trevi Therapeutics Concludes Enrollment for Phase 2 CANAL Trial in IPF Chronic Cough Trevi Therapeutics, Inc. (Nasdaq: TRVI) is a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER). ...
Previously Announced Statistically Significant Interim Analysis Established Proof of Concept (p-value less than 0.0001) Efficacy and Safety Data Expected on the Full Set of Subjects in Third Quarter 2022 NEW HAVEN, Conn. , March 15, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc.
Read more →TRVI▲ +8.2%on this news
Trevi Therapeutics to Report Q4 and Year End 2021 Financial Results and Provide a Corporate Update on March 17, 2022 Trevi Therapeutics, Inc. (Nasdaq: TRVI) is a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER). ...
NEW HAVEN, Conn. , March 9, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI ) is a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER). Today, Trevi announced that management will host a conference call and live audi
Read more →TRVI▲ +6.5%on this news· ran to +89% by day 3
Trevi Therapeutics Reports Statistically Significant Result on Interim Analysis from the Ph2 CANAL Trial of Nalbuphine ER in the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis Trevi Therapeutics, Inc. (Nasdaq: TRVI) today announced positive interim analysis results of the Phase 2 Cough And NALbuphine (CANAL) trial of its...
NEW HAVEN, Conn. , Feb. 24, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI ) today announced positive interim analysis results of the Phase 2 C ough A nd NAL buphine (CANAL) trial of its investigational therapy Haduvio™ (nalbuphine ER) in idiopathic pulmonary fibrosi
Read more →TRVI▲ +9.8%on this news
Trevi Therapeutics Completes Enrollment for Phase 2b/3 PRISM Study in Chronic Pruritus in PN Trevi Therapeutics, Inc. (Nasdaq: TRVI) is a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER)...
NEW HAVEN, Conn. , Feb. 1, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI ) is a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions. Today, Trevi announced that i
Read more →TRVITrevi Therapeutics Announces Clinical Trial Updates for Lead Indications Trevi Therapeutics, Inc. (Nasdaq: TRVI) is a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER)...
NEW HAVEN, Conn. , Jan. 5, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI ) is a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions. Today, Trevi announced that i
Read more →TRVITrevi Therapeutics to Attend Multiple Conferences in January 2022 Trevi Therapeutics, Inc. (Nasdaq: TRVI) is a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER)...
NEW HAVEN, Conn. , Dec. 16, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI ) is a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions. Today, Trevi announced that
Read more →TRVITrevi Therapeutics to Present at 5th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of the...
NEW HAVEN, Conn. , Nov. 15, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI ), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated
Read more →TRVITrevi Therapeutics Announces Third Quarter 2021 Financial Results and Business Update Phase 2b/3 PRISM (Chronic Pruritus in PN) Trial Approximately 90% Enrolled, Top-Line Data Readout Expected First Half of 2022 Phase 2
Trevi Therapeutics Announces Third Quarter 2021 Financial Results and Business Update Phase 2b/3 PRISM (Chronic Pruritus in PN) Trial Approximately 90% Enrolled, Top-Line Data Readout Expected First Half of 2022 Phase 2 CANAL (Chronic Cough in IPF) Actively Enrolling, Top-Lin
Read more →TRVITrevi Therapeutics to Present at Stifel 2021 Virtual Healthcare Conference Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of the...
NEW HAVEN, Conn. , Nov. 9, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI ), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated c
Read more →TRVITrevi Therapeutics to Report Q3 2021 Financial Results and Provide a Corporate Update on Wednesday, November 10, 2021 Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of an...
NEW HAVEN, Conn. , Nov. 3, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI ), a clinical-stage biopharmaceutical company focused on the development and commercialization of an investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated co
Read more →TRVI▼ -8.4%on this newsshared move
Trevi Therapeutics to Present at 11th World Congress on Itch (WCI) Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of the...
NEW HAVEN, Conn. , Oct. 13, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI ), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated
Read more →TRVITrevi Therapeutics Participating in Alliance Global Partners' Virtual Biotech & Specialty Pharma Conference Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of the...
NEW HAVEN, Conn. , Oct. 7, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI ), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated c
Read more →TRVITrevi Therapeutics Announces $11.8 Million Private Placement Priced At-the-Market Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of an...
NEW HAVEN, Conn. , Sept. 30, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI ), a clinical-stage biopharmaceutical company focused on the development and commercialization of an investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated
Read more →TRVITrevi Therapeutics Announces Second Quarter 2021 Financial Results and Business Update Phase 2b/3 PRISM (Chronic Pruritus in PN) Trial Approximately 80% Enrolled, Top-Line Data Readout Expected First Half of 2022 Phase 2
Trevi Therapeutics Announces Second Quarter 2021 Financial Results and Business Update Phase 2b/3 PRISM (Chronic Pruritus in PN) Trial Approximately 80% Enrolled, Top-Line Data Readout Expected First Half of 2022 Phase 2 CANAL (Chronic Cough in IPF) Trial Recruiting, Top-Line D
Read more →TRVITrevi Therapeutics Announces Additions to the Senior Leadership Team Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of the...
NEW HAVEN, Conn. , Aug. 9, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI ), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated c
Read more →TRVITrevi Therapeutics to Report Q2 2021 Financial Results on August 12 Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of an...
NEW HAVEN, Conn. , Aug. 5, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI ), a clinical-stage biopharmaceutical company focused on the development and commercialization of an investigational therapy Haduvio ™ (nalbuphine ER) to treat serious neurologically mediated c
Read more →TRVIStatements contained in this presentation and oral statements made regarding the subject of this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Pri
Investor Presentation July 2021 Exhibit Statements contained in this presentation and oral statements made regarding the subject of this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Li
Read more →TRVIFIRST A mendment to Loan and security agreement This First Amendment to Loan and Security Agreement (this "Amendment") is entered into this 6th day of July 2021, by and between SILICON VALLEY BANK ("Bank") and TREVI THER
Loan and security agreement This First Amendment to Loan and Security Agreement (this "Amendment") is entered into this 6th day of July 2021, by and between SILICON VALLEY BANK ("Bank") and TREVI THERAPEUTICS, INC., a Delaware corporation ("Borrower") whose address is 195 Church
Read more →TRVIPURCHASE AGREEMENT THIS PURCHASE AGREEMENT (the Agreement ), dated as of
THIS PURCHASE AGREEMENT (the Agreement ), dated as of June 18, 2021, is made by and between TREVI THERAPEUTICS, INC., a Delaware corporation (the Company ), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the Investor ). Capitalized terms used herein a
Read more →TRVITrevi Therapeutics to Present at 2021 BIO Digital Conference Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of the...
NEW HAVEN, Conn. , June 9, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI ), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated c
Read more →TRVITrevi Therapeutics Announces First Quarter 2021 Financial Results and Business Update Phase 2b/3 PRISM (Chronic Pruritus in PN) Trial Over 70% Enrolled Phase 2 CANAL (Chronic Cough in IPF) Trial Resumes Screening at Mult
Trevi Therapeutics Announces First Quarter 2021 Financial Results and Business Update Phase 2b/3 PRISM (Chronic Pruritus in PN) Trial Over 70% Enrolled Phase 2 CANAL (Chronic Cough in IPF) Trial Resumes Screening at Multiple Sites Fast Track Designation Granted by FDA for Mode
Read more →TRVITrevi Therapeutics to Report Q1 2021 Financial Results on May 13 Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of an...
NEW HAVEN, Conn. , May 6, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ: TRVI ), a clinical-stage biopharmaceutical company focused on the development and commercialization of an investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated con
Read more →TRVITrevi Therapeutics to Present at 20th Annual Needham Virtual Healthcare Conference
Trevi Therapeutics, a clinical-stage biopharmaceutical company, will present at the 20th Annual Needham Virtual Healthcare Conference on April 14, 2021. The presentation will include a virtual fireside chat and investor meetings. Trevi is focused on developing Haduvio for various neurologically mediated conditions and is conducting multiple clinical trials.
Read more →TRVITrevi Therapeutics Announces Fourth Quarter and Year End 2020 Financial Results and Business Updates
Trevi Therapeutics reported its financial results for Q4 and the year ending December 31, 2020. The company anticipates completing enrollment in its Phase 2b/3 PRISM trial by Q3 2021, with top-line data expected in Q4 2021. Despite challenges from COVID-19, recruitment has accelerated, and the company believes its cash reserves will sustain operations into mid-2022.
Read more →TRVITrevi Therapeutics to Report Q4 and Year End 2020 Financial Results on March 25
Trevi Therapeutics, a clinical-stage biopharmaceutical company, will host a conference call on March 25, 2021, to discuss its Q4 and year-end financial results for 2020. The call will provide updates on the company's progress, including its ongoing clinical trials for Haduvio, an investigational drug aimed at treating serious neurologically mediated conditions. Haduvio's unique formulation and mechanism of action are designed to address chronic pruritus and other conditions.
Read more →TRVITrevi Therapeutics to Present at 10th Annual SVB Leerink Global Healthcare Conference
Trevi Therapeutics, Inc. will present at the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021. The company will participate in a virtual fireside chat and host investor meetings. Trevi is developing Haduvio, an investigational drug for treating chronic pruritus, chronic cough, and levodopa-induced dyskinesia. The company is currently conducting Phase 2b/3 and Phase 2 trials for these conditions.
Read more →TRVITrevi Therapeutics Appoints William Forbes, Pharm.D. as Chief Development Officer
Trevi Therapeutics has appointed William Forbes, Pharm.D., as Chief Development Officer to lead the clinical development of Haduvio™. Forbes, with over 30 years of experience, will oversee late-stage trials for chronic pruritus and chronic cough. His expertise is expected to enhance Trevi's efforts in addressing serious conditions lacking approved therapies.
Read more →TRVITrevi Therapeutics Announces Third Quarter 2020 Financial Results and Business Update PRISM Trial of Haduvio for Severe Pruritus in Patients with Prurigo Nodularis Exceeds Halfway Enrollment Milestone Phase 2 Chronic Cou
Trevi Therapeutics Announces Third Quarter 2020 Financial Results and Business Update PRISM Trial of Haduvio for Severe Pruritus in Patients with Prurigo Nodularis Exceeds Halfway Enrollment Milestone Phase 2 Chronic Cough Trial in Patients with IPF Enrolled First New Subject
Read more →TRVITrevi Therapeutics to Present at Stifel Healthcare Conference
NEW HAVEN, Conn., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announce
Read more →TRVITrevi Therapeutics to Report Q3 2020 Financial Results on November 11
Trevi Therapeutics, a clinical-stage biopharmaceutical company, will report its Q3 2020 financial results on November 11, 2020. The company is focused on developing Haduvio, an investigational drug for treating serious neurologically mediated conditions. A conference call and webcast will provide updates and financial insights.
Read more →TRVITrevi Therapeutics Provides Clinical Trial Updates for Haduvio™
Trevi Therapeutics has resumed patient screening for its Phase 2 trial of Haduvio for chronic cough in IPF patients, which had been paused due to COVID-19. The company also announced that its Phase 2b/3 PRISM trial for severe pruritus has reached 50% enrollment. The amended trial protocols aim to enhance patient safety during the pandemic.
Read more →TRVITrevi Therapeutics Announces the Hiring of Key Talent
Trevi Therapeutics has appointed three key executives to strengthen its leadership team. Shashank Rohatagi, Ph.D., will oversee pharmacology and clinical pharmacokinetics; Farrell Simon, Pharm.D., will lead U.S. marketing; and Katherine S. Takaki, Ph.D., will manage global regulatory affairs. These appointments aim to advance the development of Haduvio, targeting conditions with no approved therapies.
Read more →TRVITrevi Therapeutics to Present at H.C. Wainwright Global Investment Conference
NEW HAVEN, Conn., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announc
Read more →TRVITREVI THERAPEUTICS ANNOUNCES SECOND QUARTER 2020 FINANCIAL RESULTS AND BUSINESS UPDATE Announced Positive Outcome of Sample Size Re-Estimation Analysis for PRISM Trial Strong Enrollment in PRISM Trial After Lifting of CO
TREVI THERAPEUTICS ANNOUNCES SECOND QUARTER 2020 FINANCIAL RESULTS Announced Positive Outcome of Sample Size Re-Estimation Analysis for PRISM Trial Strong Enrollment in PRISM Trial After Lifting of COVID-19 Restrictions Announces $14 Million Term Loan - Cash Position Expected
Read more →TRVITrevi Therapeutics to Report Q2 2020 Financial Results on August 13
NEW HAVEN, Conn., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announce
Read more →TRVITrevi Therapeutics to Present at BTIG Virtual Biotechnology Conference
NEW HAVEN, Conn., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announce
Read more →TRVITrevi Therapeutics Announces Positive Outcome of the Sample Size Re-Estimation Analysis in PRISM Trial for Severe Pruritus in Patients With Prurigo Nodularis
Independent Data Monitoring Committee Recommends Continuation of PRISM Trial with Expansion to 360 Subjects per the Adaptive Design Enrollment Expected to be Complete by Third Quarter 2021 Introducing HADUVIO™ as Proposed Trade Name for Nalbuphine ER NEW HAVEN, Conn., July 13,
Read more →TRVITrevi Therapeutics Announces Election of Dominick C. Colangelo to Board of Directors Seasoned biopharmaceutical executive with over 20 years of executive leadership and corporate development experience New Haven, Conn.
Trevi Therapeutics Announces Election of Dominick C. Colangelo to Seasoned biopharmaceutical executive with over 20 years of executive leadership and corporate development experience New Haven, Conn., June 30, 2020 Trevi Therapeutics, Inc. ( Trevi ), a clinical-stage biopharmac
Read more →TRVITrevi Therapeutics to Present at BMO Prescriptions for Success Healthcare Virtual Conference
NEW HAVEN, Conn., June 17, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced that mana
Read more →TRVITrevi Therapeutics to Hold Virtual 2020 Annual Meeting of Stockholders
NEW HAVEN, Conn., May 29, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced that, due
Read more →TRVITREVI THERAPEUTICS ANNOUNCES FIRST QUARTER 2020 FINANCIAL RESULTS AND CORPORATE UPDATE Sample Size Re-Estimation Analysis for PRISM Trial Expected in Mid-2020 New Patient Screening Re-Starting at PRISM Sites in the US an
TREVI THERAPEUTICS ANNOUNCES FIRST QUARTER 2020 FINANCIAL RESULTS AND CORPORATE UPDATE Sample Size Re-Estimation Analysis for PRISM Trial Expected in Mid-2020 New Patient Screening Re-Starting at PRISM Sites in the US and Europe Cash Position of $52.6 Million Expected to Fund
Read more →TRVITREVI THERAPEUTICS TO PRESENT AT NEEDHAM HEALTHCARE CONFERENCE
NEW HAVEN, Conn., April 08, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced that man
Read more →TRVITREVI THERAPEUTICS ANNOUNCES FOURTH QUARTER AND YEAR END 2019 FINANCIAL RESULTS AND CORPORATE UPDATE Enrollment in PRISM Study Progressing - Sample Size Re-estimation Planned for mid-2020 Expect to Report Top-Line Data i
TREVI THERAPEUTICS ANNOUNCES FOURTH QUARTER AND YEAR END 2019 FINANCIAL RESULTS AND CORPORATE UPDATE Enrollment in PRISM Study Progressing - Sample Size Re-estimation Planned for mid-2020 Expect to Report Top-Line Data in both PN and IPF-Cough Trials in Second Half of 2020 Ca
Read more →TRVITrevi Therapeutics to Present at SVB Leerink Healthcare Conference
NEW HAVEN, Conn., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced that mana
Read more →TRVITrevi Therapeutics Announces Election of James V. Cassella, Ph.D. to Board of Directors Seasoned biopharmaceutical executive with over 30 years of drug development experience New Haven, Conn.
Trevi Therapeutics Announces Election of James V. Cassella, Ph.D. to Seasoned biopharmaceutical executive with over 30 years of drug development experience Conn., February 18, 2020 Trevi Therapeutics, Inc. ( Trevi ), a clinical-stage biopharmaceutical company focused on the de
Read more →TRVITREVI THERAPEUTICS ANNOUNCES THIRD QUARTER 2019 FINANCIAL RESULTS AND RECENT BUSINESS DEVELOPMENTS Advancement of Nalbuphine ER in Clinical Development for Three Indications Cash Position of $63.5 Million Expected to Fun
TREVI THERAPEUTICS ANNOUNCES THIRD QUARTER 2019 FINANCIAL RESULTS AND RECENT BUSINESS DEVELOPMENTS Advancement of Nalbuphine ER in Clinical Development for Three Indications Cash Position of $63.5 Million Expected to Fund Operations Through At Least Q1 2021 New Haven, CT, Nov
Read more →TRVITrevi Therapeutics to Participate in Panel Discussion at BTIG Pain / Pruritus Management Forum
NEW HAVEN, Conn., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced that Jen
Read more →TRVITREVI THERAPEUTICS ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS AND RECENT BUSINESS DEVELOPMENTS Advancement of Nalbuphine ER Through Clinical Development in Multiple Indications New Haven, CT
TREVI THERAPEUTICS ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS AND RECENT BUSINESS DEVELOPMENTS Advancement of Nalbuphine ER Through Clinical Development in Multiple Indications New Haven, CT, August 12, 2019 Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopha
Read more →TRVITrevi Therapeutics to Present at BMO Prescriptions for Success Healthcare Conference
NEW HAVEN, Conn., June 18, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced that Comp
Read more →TRVITREVI THERAPEUTICS ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS AND RECENT BUSINESS DEVELOPMENTS Raised $70 Million in Gross Proceeds from Initial Public Offering and Concurrent Private Placement Initiated Phase 2 Clin
TREVI THERAPEUTICS ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS AND RECENT BUSINESS DEVELOPMENTS Raised $70 Million in Gross Proceeds from Initial Public Offering and Concurrent Private Placement Initiated Phase 2 Clinical Trial for Chronic Cough in Patients with Idiopathic
Read more →TRVITrevi Therapeutics Announces Pricing of Initial Public Offering
NEW HAVEN, Conn., May 07, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced the pricing of
Read more →Competitive Position
How TRVI ranks across every disease it competes inCompetitive Position is a premium feature
See how TRVI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial